Short answer
Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 2.05 (Costs Associated with Exit or Disposal Activities), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
Emergent BioSolutions Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial and operating details
- Investor focus: quarterly performance, operating trends, and management outlook in the attached release
Item 2.05 · Costs Associated with Exit or Disposal Activities
- Workforce reduction: 93 employees plus 21 vacant positions, with wet-laboratory closures in Gaithersburg, Maryland
- Expected annualized savings of approximately $40 million when fully implemented
- Estimated restructuring charges of $10 million–$11.5 million, primarily in the second half of 2026
- Primarily cash costs for severance, transition services, and estimated benefits
- Savings and charges remain subject to local-law requirements and implementation risks
Item 5.02 · Departure/Election of Directors or Officers
- Chief Medical Officer and Head of R&D role eliminated effective August 19, 2026
- Simon Lowry departing, creating leadership transition across medical and research functions
- Stephanie Duatschek promoted to Executive Vice President, Chief Growth Officer
- Duatschek retains responsibility for strategic growth and reports to CEO Joseph Papa
Item 7.01 · Regulation FD Disclosure
- August 5, 2026 conference call covering quarter ended June 30, 2026
- Earnings Call Slides furnished as Exhibit 99.2 and available on Emergent’s website
- Investor focus: quarterly operating results and management commentary during the call
- Restructuring Plan timing, total cash cost, and expected annualized savings identified as key forward-looking topics
- Forward-looking statements subject to execution risks and no commitment to update guidance
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $234.3M, up 66%, driven by $109.6M MCM growth from U.S. government contract timing
- Adjusted EBITDA $96.5M, margin 41%, but GAAP net loss $180.2M after $191.3M non-cash NARCAN impairment
- NARCAN weakness is structural: Commercial Products revenue fell 22% and adjusted gross margin declined to 31% from 46%
- Full-year outlook sharply reduced: revenue $645–$675M, adjusted EBITDA $130–$150M, adjusted net income $10–$30M
- Restructuring targets approximately $40M annualized savings and eliminates approximately 90 roles, highlighting turnaround pressure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Emergent BioSolutions Inc. 8-K filings
Get the next EBS 8-K as it lands
Follow EBS for push alerts, or ask the research agent what this filing means.